-

Wugen to Participate in Upcoming April Investor Conferences

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in two upcoming virtual investor conferences in April:

  • 21st Annual Needham Virtual Healthcare Conference
    Format: Panel titled “Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space”
    Date/Time: Thursday, April 14, 2022 at 11:00 a.m. ET
    Location: Virtual
  • Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
    Format: Fireside Chat
    Date/Time: Tuesday, April 26, 2022 at 9 a.m. ET
    Location: Virtual

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.

Contacts

Investor:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com

Industry:

Wugen, Inc.

Release Versions
English

Contacts

Investor:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com

More News From Wugen, Inc.

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented data for its two lead programs, WU-CART-007 and WU-NK-101, in separate presentations at the European Hematology Association (EHA) 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany. “We are very encouraged by these initial safety and efficacy data...

Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced an oral presentation and an onsite poster presentation highlighting data from Wugen’s WU-NK-101 and WU-CART-007 programs at the European Hematology Association (EHA) 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany. The oral presentation includes...

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the appointment of industry veteran Mark Alles as Chair of the Board of Directors. Mr. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation. He has over 30 years of biopharmaceutical experience, and an outstanding record of driving growth a...
Back to Newsroom